Leukocyte surface antigen CD47 and DNA methyltransferase pathway (CD47-DNMT)

The CD47 and DNA methyltransferase (DNMT) pathway is a therapeutic axis that combines the blockade of the CD47 immune checkpoint with the inhibition of epigenetic enzymes. CD47 is a cell surface protein that acts as a "don't eat me" signal by binding to SIRPα on macrophages, thereby preventing the phagocytosis of both healthy and malignant cells [2, 4]. DNMT inhibitors, such as azacitidine and decitabine, are hypomethylating agents that can reactivate silenced tumor suppressor genes and upregulate pro-phagocytic "eat me" signals like calreticulin on the surface of cancer cells [3, 5]. The synergy between these two targets lies in the simultaneous removal of the inhibitory CD47 signal and the enhancement of stimulatory signals, which significantly boosts the innate immune system's ability to clear tumor cells [3, 6]. This combination has been a major focus of clinical development for myeloid malignancies, particularly in patients with high-risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [1, 2]. However, clinical trials involving agents like magrolimab have faced challenges due to safety concerns, including severe hematologic toxicities such as anemia [1, 7].

Other names

CD47-HMA axisCD47-DNMTi combinationMagrolimab-Azacitidine combinationCD47-hypomethylating agent pathway

DNA methyltransferase (DNMT) inhibitors upregulate pro-phagocytic signals (e.g., calreticulin) and tumor antigens on the surface of malignant cells, while CD47 inhibitors block the "don't eat me" signal, synergistically enhancing macrophage-mediated phagocytosis and anti-tumor immunity.